Piperazine derivatives having multimodal activity against pain
The present invention relates to compounds having dual pharmacological activity towards both the sigma (σ) receptor, and the μ-opioid receptor and more particularly to piperazine compounds having this pharmacological activity, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.
1. A compound of Formula IV:
wherein
m is 1 or 2;
n is 0 or 1;
V 1 is nitrogen or carbon;
R 1 is hydroxyl, —NR 6 R 7 , —NR 6 S(O) 2 R 7 , —NR 6 COR 7 , —NR 6 CONR 7 R 8 , —SR 6 , —S(O) 2 R 6 , —S(O) 2 NR 6 R 7 , or —CONR 6 R 7 ;
R 2 is hydrogen, halogen, —NR 6 R 7 , —SR 6 , —OR, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl;
wherein the alkyl, alkenyl or alkynyl in R 2 , if substituted, is substituted with one or more substituents selected from F, Cl, Br, I, NH 2 , SH or OH, —C(O)OH, or —OC 1-4 alkyl being unsubstituted or substituted by one or more of OH or halogen (F, Cl, I, Br);
R 3 is substituted or unsubstituted alkyl, CONR 6 R 7 , substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl or substituted or unsubstituted heterocyclyl;
R 4 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl or substituted or unsubstituted heterocyclyl;
wherein the aryl in R 3 and/or in R 4 , if a substituted aryl, is substituted with one or more substituents selected from halogen (F, Cl, I, Br), —OH, —NH 2 , —SH, —C(O)OH, —OC 1-4 alkyl being unsubstituted or substituted by one or more of OH or halogen (F, Cl, I, Br), —CN, or —C 1-4 alkyl being unsubstituted or substituted by one or more of OH or halogen (F, Cl, I, Br);
wherein the heterocyclyl or cycloalkyl in R 3 and/or in R 4 , if a substituted heterocyclyl or cycloalkyl, is substituted with one or more substituents selected from halogen (F, Cl, I, Br), —OH, —NH 2 , —SH, ═O, —C(O)OH, —OC 1-4 alkyl being unsubstituted or substituted by one or more of OH or halogen (F, Cl, I, Br), —CN, or —C 1-4 alkyl being unsubstituted or substituted by one or more of OH or halogen (F, Cl, I, Br);
wherein the alkyl, alkenyl or alkynyl in R 3 and/or in R 4 , if substituted, is substituted with one or more substituents selected from F, Cl, Br, I, NH 2 , SH or OH, —C(O)OH, or —OC 1-4 alkyl being unsubstituted or substituted by one or more of OH or halogen (F, Cl, I, Br);
R 5 is hydrogen, hydroxy, or CH 3 ;
R 6 , R 7 and R 8 are independent from each other and selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl;
wherein the aryl in R 6 , in R 7 , and/or in R 8 , if a substituted aryl, is substituted with one or more substituents selected from halogen (F, Cl, I, Br), —OH, —NH 2 , —SH, —C(O)OH, —OC 1-4 alkyl being unsubstituted or substituted by one or more of OH or halogen (F, Cl, I, Br), —CN, or —C 1-4 alkyl being unsubstituted or substituted by one or more of OH or halogen (F, Cl, I, Br);
wherein the heterocyclyl or cycloalkyl in in R 6 , in R 7 , and/or in R 8 , if a substituted heterocyclyl or cycloalkyl, is substituted with one or more substituents selected from halogen (F, Cl, I, Br), —OH, —NH 2 , —SH, ═O, —C(O)OH, —OC 1-4 alkyl being unsubstituted or substituted by one or more of OH or halogen (F, Cl, I, Br), —CN, or —C 1-4 alkyl being unsubstituted or substituted by one or more of OH or halogen (F, Cl, I, Br);
wherein the alkyl, alkenyl or alkynyl in R 6 , in R 7 , and/or in R 8 , if substituted, is substituted with one or more substituents selected from F, Cl, Br, I, NH 2 , SH or OH, —C(O)OH, or —OC 1-4 alkyl being unsubstituted or substituted by one or more of OH or halogen (F, Cl, I, Br);
and W, Y and Z are independently N or CH with only 1 or 2 of them being CH;
and wherein
is selected from
optionally as a stereoisomer, including enantiomers and diastereomers, a racemate or a mixture of at least two stereoisomers, including enantiomers and/or diastereomers, in any mixing ratio, or a salt thereof;
with the following proviso:
with the proviso that if V 1 is carbon, 2 of W, Y and Z are CH, n is 0 and R 3 is —CH 3 or —C 2 H 5 , then R 1 may not be —NH 2 .
2. The compound according to claim 1 , wherein
R 3 is CONR 6 R 7 , substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl or substituted or unsubstituted heterocyclyl.
3. The compound according to claim 2 , wherein R is substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl.
4. The compound according to claim 1 , which is a compound of Formula V:
wherein
m is 1 or 2;
n is 0 or 1;
V 1 is nitrogen or carbon;
R 1 is hydroxyl, —NR 6 R 7 , —NR 6 S(O) 2 R 7 , —NR 6 COR 7 , —NR 6 CONR 7 R 8 , —SR 6 , —S(O) 2 R 6 , —S(O) 2 NR 6 R 7 , or —CONR 6 R 7 ;
R 2 is hydrogen, halogen, —NR 6 R 7 , —SR 6 , —OR 6 , substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl;
R 3 is substituted or unsubstituted alkyl, CONR 6 R 7 , substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl or substituted or unsubstituted heterocyclyl;
R 4 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted of unsubstituted aryl or substituted of unsubstituted heterocyclyl;
R 5 is hydrogen, hydroxy, or CH 3 ;
R 6 , R 7 and R 8 are independent from each other and selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl;
and wherein
is selected from
optionally as a stereoisomer, including enantiomers and diastereomers, a racemate or a mixture of at least two stereoisomers, including enantiomers and/or diastereomers, in any mixing ratio, or a salt thereof.
5. The compound according to claim 1 , wherein
R 1 is hydroxyl, —NR 6 R 7 , —NR 6 S(O) 2 R 7 , —SR 6 , —S(O) 2 R 6 , or —S(O) 2 NR 6 R 7 ;
R 1 is hydrogen, halogen, —NR 6 R 7 , —SR 6 , —OR 6 , substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl, wherein
the alkyl is C 1-8 alkyl;
the alkenyl is C 2-10 -alkenyl;
the alkynyl is C 2-10 -alkynyl;
the halogen is fluorine, chlorine, iodine or bromine;
R 3 is substituted or unsubstituted alkyl, CONR 6 R 7 , substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl or substituted or unsubstituted heterocyclyl, wherein
the aryl is phenyl, naphthyl or anthracene;
the heterocyclyl is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur;
the alkyl is C 1-8 alkyl;
the alkenyl is C 2-10 -alkenyl;
the alkynyl is C 2-10 -alkynyl;
the cycloalkyl is C 3-8 cycloalkyl;
R 4 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl or substituted or unsubstituted heterocyclyl, wherein
the aryl is phenyl, naphthyl or anthracene;
the heterocyclyl is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur;
the alkyl is C 1-8 alkyl;
the alkenyl is C 2-10 -alkenyl;
the alkynyl is C 2-10 -alkynyl;
the cycloalkyl is C 3-8 cycloalkyl;
R 5 is hydrogen, hydroxy, or CH 3 ;
R 6 , R 7 and R 8 are independent from each other and selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl, wherein
the aryl is phenyl, naphthyl or anthracene;
the heterocyclyl is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur;
the alkyl is C 1-8 alkyl;
the alkenyl is C 2-10 -alkenyl;
the alkynyl is C 2-10 -alkynyl;
the cycloalkyl is C 3-8 cycloalkyl.
6. The compound according to claim 1 , wherein
R 1 is hydroxyl, —NR 6 R 7 , —NR 6 S(O) 2 R 7 , —NR 6 COR 7 , —NR 6 CONR 7 R 8 , —S(O) 2 R 6 , —S(O) 2 NR 6 R 7 , or —CONR 6 R 7 ;
R 2 is hydrogen, fluorine, CH 3 or CF 3 ;
R 3 is substituted or unsubstituted propyl or butyl, diethylacetamide, substituted or unsubstituted cyclopentyl or cyclohexyl, substituted or unsubstituted phenyl, or substituted or unsubstituted pyridyl, imidazolyl, indenyl, 2,3-dihydroindenyl, benzofuryl, or pyrimidinyl;
R 4 is hydrogen, CH 3 or CH 2 OH;
R 5 is hydrogen or CH 3 ; and
R 6 , R 7 , and R 8 are independently from each other selected from the group consisting of hydrogen, substituted or unsubstituted methyl, ethyl, propyl or butyl, substituted or unsubstituted phenyl, substituted or unsubstituted pyrrolidinyl, or substituted or unsubstituted cyclopropyl.
7. The compound according to claim 1 , wherein
m is 1 or 2;
n is 0 or 1;
V 1 is nitrogen or carbon;
R 1 is hydroxyl, —NR 6 R 7 , —NR 6 S(O) 2 R 7 , —NR 6 COR 7 , —NR 6 CONR 7 R 8 , —S(O) 2 R 6 , —S(O) 2 NR 6 R 7 , or —CONR 6 R 7 ;
R 2 is hydrogen, halogen, or C 1-4 alkyl;
R 3 is selected from substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heterocyclyl;
R 4 is hydrogen or substituted or unsubstituted C 1-4 alkyl;
R 5 is hydrogen, hydroxy, or CH 3 ;
R 6 , R 7 , and R 8 are independently from each other selected from hydrogen, substituted or unsubstituted C 1-4 alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, or substituted or unsubstituted cycloalkyl.
8. The compound according to claim 1 , wherein
m is 1 or 2:
n is 0 or 1;
V 1 is nitrogen or carbon;
R 1 is hydroxyl, —NR 6 R 7 , —NR S(O) 2 R 7 , —NR 6 COR 7 , —NR 6 CONR 7 R 8 , —S(O) 2 R 6 , —S(O) 2 NR 6 R 7 , or —CONR 6 R 7 ;
R 2 is hydrogen;
R 3 is substituted or unsubstituted cyclopentyl, cyclohexyl, substituted or unsubstituted phenyl, or substituted or unsubstituted pyridyl, imidazolyl, indenyl, 2,3-dihydroindenyl, benzofuryl, or pyrimidinyl;
R 4 is hydrogen or substituted or unsubstituted C 1-4 alkyl;
R 5 is hydrogen, hydroxy, or CH 3 ;
R 6 , R 7 and R 8 are independent from each other and selected from the group consisting of hydrogen, substituted or unsubstituted C 1-4 alkyl, substituted or unsubstituted C 3-6 cycloalkyl, and substituted or unsubstituted phenyl;
and W, Y and Z are independently from one another N or CH with only 1 or 2 of them being CH;
and wherein
is selected from
optionally as a stereoisomer, including enantiomers and diastereomers, a racemate or a mixture of at least two stereoisomers, including enantiomers and/or diastereomers, in any mixing ratio, or a salt thereof.
9. The compound according to claim 1 , which is selected from:
N-(3-(4-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenyl)propane-2-sulfonamide,
N-(6-(4-((1-(5-chloropyridin-3-yl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)propane-2-sulfonamide,
N-(3-(4-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenyl)methanesulfonamide,
N-(3-(4-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenyl)methanesulfonamide,
3-(4-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenol,
3-(4-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenol,
3-(4-((1-(pyridin-2-yl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenol,
N-(3-(4-((1-(6-(trifluoromethyl)pyridin-3-yl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenyl)methanesulfonamide,
N-(3-(4-((1-(2-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenyl)propane-2-sulfonamide,
N-(3-(4-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenyl)ethanesulfonamide,
N-(3-(4-((1-(pyridin-2-ylmethyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenyl)propane-2-sulfonamide,
N-(3-(4-((1-(pyridin-2-yl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenyl)propane-2-sulfonamide,
1,1,1-trifluoro-N-(3-(4-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenyl)methanesulfonamide,
N-(3-(4-((1-(5-fluoropyridin-2-yl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenyl)propane-2-sulfonamide,
N-(3-(4-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenyl)cyclopropanesulfonamide,
N-(3-(4-((1-(3-fluoropyridin-2-yl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenyl)propane-2-sulfonamide,
N-(3-(4-((1-(4-fluoropyridin-2-yl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenyl)propane-2-sulfonamide,
N-(3-((1R,5S)-3-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)-3,8-diazabicyclo[3.2.1]octan-8-yl)phenyl)methanesulfonamide,
N-(3-(4-((2-(pyridin-2-yl)-2H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenyl)propane-2-sulfonamide,
N-(3-(4-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)-1,4-diazepan-1-yl)phenyl)methanesulfonamide,
N-(3-(4-((1-(3-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenyl)propane-2-sulfonamide,
N-(3-(4-((1-(4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenyl)propane-2-sulfonamide,
N-(3-(4-((1-(6-fluoropyridin-2-yl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenyl)propane-2-sulfonamide,
3-(4-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)aniline,
N-tert-butyl-3-(4-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)benzenesulfonamide,
N-(3-(4-((1-phenyl-1H-pyrazol-4-yl)methyl)piperazin-1-yl)phenyl)methanesulfonamide,
N-(3-(4-((1-benzyl-1H-pyrazol-4-yl)methyl)piperazin-1-yl)phenyl)methanesulfonamide,
N-(3-(4-((1-(pyridin-2-ylmethyl)-1H-pyrazol-4-yl)methyl)piperazin-1-yl)phenyl)methanesulfonamide,
N-(3-(4-((1-phenyl-1H-pyrazol-4-yl)methyl)piperazin-1-yl)phenyl)propane-2-sulfonamide,
3-(4-((1-phenyl-1H-pyrazol-4-yl)methyl)piperazin-1-yl)phenol,
N-(3-(4-((1-(pyridin-2-yl)-1H-pyrazol-4-yl)methyl)piperazin-1-yl)phenyl)methanesulfonamide,
N-(3-(4-((1-(pyridin-2-yl)-1H-pyrazol-4-yl)methyl)piperazin-1-yl)phenyl)propane-2-sulfonamide,
N-(3-(4-((1-benzyl-1H-imidazol-4-yl)methyl)piperazin-1-yl)phenyl)propane-2-sulfonamide,
N-(6-(4-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)methanesulfonamide,
N-(6-(4-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)propane-2-sulfonamide,
N-(6-(4-((1-(2-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)propane-2-sulfonamide,
N-(6-(4-((1-(2-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)cyclopropanesulfonamide,
N-(6-(4-((1-(2-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)propionamide,
N-(6-(4-((1-(2-hydroxyphenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazine-1-yl)pyridin-2-yl)propane-2-sulfonamide,
N-(6-(4-((1-(pyridin-2-yl)-1H-pyrazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)propane-2-sulfonamide,
N-(6-(4-((1-(2,6-difluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)propane-2-sulfonamide,
N-(6-(4-((1-(3,4-difluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)propane-2-sulfonamide,
N-(6-(4-((1-(4-chloro-2-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-ylpyridin-2-yl)propane-2-sulfonamide,
N-(6-(4-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)cyclopropanesulfonamide,
N-(5-chloro-6-(4-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)propane-2-sulfonamide,
N-(6-(4-((1-(5-methoxypyridin-3-yl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)propane-2-sulfonamide,
N-(6-(4-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)-1,4-diazepan-1-yl)pyridin-2-yl)propane-2-sulfonamide,
N-(6-(4-((1-(5-chloropyridin-2-yl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)propane-2-sulfonamide,
N-(6-(4-((1-(pyridin-2-ylmethyl)-1H-1,2,3-triazol-4-yl)methyl)-1,4-diazepan-1-yl)pyridin-2-yl)propane-2-sulfonamide,
N-(6-(4-((1-(2-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-1,4-diazepan-1-yl)pyridin-2-yl)propane-2-sulfonamide,
N-(6-(4-((1-(pyridin-2-yl)-1H-imidazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)propane-2-sulfonamide,
6-(4-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)pyridin-2-amine,
N-(6-(4-((1-(3-fluoropyridin-2-yl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)cyclopropanesulfonamide,
N-(6-(4-((1-(2,5-difluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)cyclopropanesulfonamide,
N-(6-(4-((1-(2-fluoro-5-methylphenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)cyclopropanesulfonamide,
N-(6-(4-((1-(5-(trifluoromethyl)pyridin-2-yl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)cyclopropanesulfonamide,
N-(6-(4-((1-(4-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)cyclopropanesulfonamide,
N-(6-(4-((1-(2-fluoro-4-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)cyclopropanesulfonamide,
N-(6-(4-((1-phenyl-1H-imidazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)cyclopropanesulfonamide,
N-(6-(4-((1-(2-fluorophenyl)-1H-imidazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)cyclopropanesulfonamide,
6-(4-((1-(2-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)pyridin-2-amine, and
N-(6-(4-((1-(pyridin-2-yl)-1H-imidazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)cyclopropanesulfonamide,
optionally as a stereoisomer, including enantiomers and diastereomers, a racemate or a mixture of at least two stereoisomers, including enantiomers and/or diastereomers, in any mixing ratio, or a salt thereof.
10. The compound according to claim 9 , which is selected from:
N-(3-(4-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenyl)propane-2-sulfonamide,
N-(6-(4-((1-(5-chloropyridin-3-yl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)propane-2-sulfonamide,
N-(3-(4-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenyl)methanesulfonamide,
N-(3-(4-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenyl)methanesulfonamide,
3-(4-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenol,
3-(4-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenol,
3-(4-((1-(pyridin-2-yl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenol,
N-(3-(4-((1-(2-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenyl)propane-2-sulfonamide,
N-(3-(4-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenyl)ethanesulfonamide,
N-(3-(4-((1-(pyridin-2-ylmethyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenyl)propane-2-sulfonamide,
N-(3-(4-((1-(pyridin-2-yl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenyl)propane-2-sulfonamide,
N-(3-(4-((1-(5-fluoropyridin-2-yl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-yl)phenyl)propane-2-sulfonamide,
N-(3-(4-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenyl)cyclopropanesulfonamide,
N-(3-(4-((1-(3-fluoropyridin-2-yl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenyl) propane-2-sulfonamide,
N-(3-(4-((1-(4-fluoropyridin-2-yl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenyl)propane-2-sulfonamide,
N-(3-((1R,5S)-3-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)-3,8-diazabicyclo[3.2.1]octan-8-yl)phenyl)methanesulfonamide,
N-(3-(4-((2-(pyridin-2-yl)-2H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenyl)propane-2-sulfonamide,
N-(3-(4-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)-1,4-diazepan-1-yl)phenyl)methanesulfonamide,
N-(3-(4-((1-(3-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenyl) propane-2-sulfonamide,
N-(3-(4-((1-(4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenyl)propane-2-sulfonamide,
N-(3-(4-((1-(6-fluoropyridin-2-yl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenyl)propane-2-sulfonamide,
N-tert-butyl-3-(4-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)benzenesulfonamide,
N-(3-(4-((1-phenyl-1H-pyrazol-4-yl)methyl)piperazin-1-yl)phenyl)methanesulfonamide,
N-(3-(4-((1-benzyl-1H-pyrazol-4-yl)methyl)piperazin-1-yl)phenyl)methanesulfonamide,
N-(3-(4-((1-(pyridin-2-ylmethyl)-1H-pyrazol-4-yl)methyl)piperazin-1-yl)phenyl)methanesulfonamide,
N-(3-(4-((1-phenyl-1H-pyrazol-4-yl)methyl)piperazin-1-yl)phenyl)propane-2-sulfonamide,
3-(4-((1-phenyl-1H-pyrazol-4-yl)methyl)piperazin-1-yl)phenol,
N-(3-(4-((1-(pyridin-2-yl)-1H-pyrazol-4-yl)methyl)piperazin-1-yl)phenyl)methanesulfonamide,
N-(3-(4-((1-(pyridin-2-yl)-1H-pyrazol-4-yl)methyl)piperazin-1-yl)phenyl)propane-2-sulfonamide,
N-(3-(4-((1-benzyl-1H-imidazol-4-yl)methyl)piperazin-1-yl)phenyl)propane-2-sulfonamide,
N-(6-(4-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)methanesulfonamide,
N-(6-(4-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)propane-2-sulfonamide,
N-(6-(4-((1-(2-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)propane-2-sulfonamide,
N-(6-(4-((1-(2-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)cyclopropanesulfonamide,
N-(6-(4-((1-(2-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)propionamide,
N-(6-(4-((1-(2-hydroxyphenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)propane-2-sulfonamide,
N-(6-(4-((1-(pyridin-2-yl)-1H-pyrazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)propane-2-sulfonamide,
N-(6-(4-((1-(2,6-difluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)propane-2-sulfonamide,
N-(6-(4-((1-(3,4-difluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)propane-2-sulfonamide,
N-(6-(4-((1-(4-chloro-2-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)propane-2-sulfonamide,
N-(6-(4-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)cyclopropanesulfonamide,
N-(5-chloro-6-(4-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)propane-2-sulfonamide,
N-(6-(4-((1-(5-methoxypyridin-3-yl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)propane-2-sulfonamide,
N-(6-(4-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)-1,4-diazepan-1-yl)pyridin-2-yl)propane-2-sulfonamide,
N-(6-(4-((1-(5-chloropyridin-2-yl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)propane-2-sulfonamide,
N-(6-(4-((1-(pyridin-2-ylmethyl)-1H-1,2,3-triazol-4-yl)methyl)-1,4-diazepan-1-yl)pyridin-2-yl)propane-2-sulfonamide,
N-(6-(4-((1-(2-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-1,4-diazepan-1-yl)pyridin-2-yl)propane-2-sulfonamide, and
N-(6-(4-((1-(pyridin-2-yl)-1H-imidazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)propane-2-sulfonamide,
optionally as a stereoisomer, including enantiomers and diastereomers, a racemate or a mixture of at least two stereoisomers, including enantiomers and/or diastereomers, in any mixing ratio, or a salt thereof.
11. The compound according to claim 9 , which is selected from:
N-(3-(4-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenyl)propane-2-sulfonamide,
N-(3-(4-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenyl)methanesulfonamide,
3-(4-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenol,
N-(3-(4-((1-(2-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenyl)propane-2-sulfonamide,
N-(3-(4-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenyl)ethanesulfonamide,
N-(3-(4-((1-(pyridin-2-yl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenyl)propane-2-sulfonamide,
N-(3-(4-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenyl)cyclopropanesulfonamide,
N-(3-(4-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)-1,4-diazepan-1-yl)phenyl)methanesulfonamide,
N-(3-(4-((1-(3-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenyl)propane-2-sulfonamide,
N-(3-(4-((1-(4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenyl)propane-2-sulfonamide,
N-(3-(4-((1-(6-fluoropyridin-2-yl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenyl)propane-2-sulfonamide,
N-(3-(4-((1-phenyl-1H-pyrazol-4-yl)methyl)piperazin-1-yl)phenyl)methanesulfonamide,
N-(3-(4-((1-benzyl-1H-pyrazol-4-yl)methyl)piperazin-1-yl)phenyl)methanesulfonamide,
N-(3-(4-((1-phenyl-1H-pyrazol-4-yl)methyl)piperazin-1-yl)phenyl)propane-2-sulfonamide,
3-(4-((1-phenyl-1H-pyrazol-4-yl)methyl)piperazin-1-yl)phenol,
N-(3-(4-((1-(pyridin-2-yl)-1H-pyrazol-4-yl)methyl)piperazin-1-yl)phenyl)methanesulfonamide,
N-(3-(4-((1-(pyridin-2-yl)-1H-pyrazol-4-yl)methyl)piperazin-1-yl)phenyl)propane-2-sulfonamide,
N-(3-(4-((1-benzyl-1H-imidazol-4-yl)methyl)piperazin-1-yl)phenyl)propane-2-sulfonamide,
N-(6-(4-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)methanesulfonamide,
N-(6-(4-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)propane-2-sulfonamide,
N-(6-(4-((1-(2-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)propane-2-sulfonamide,
N-(6-(4-((1-(2-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)cyclopropanesulfonamide,
N-(6-(4-((1-(2-hydroxyphenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)propane-2-sulfonamide,
N-(6-(4-((1-(pyridin-2-yl)-1H-pyrazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)propane-2-sulfonamide,
N-(6-(4-((1-(3,4-difluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)propane-2-sulfonamide,
N-(6-(4-((1-(4-chloro-2-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)propane-2-sulfonamide,
N-(6-(4-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)cyclopropanesulfonamide,
N-(5-chloro-6-(4-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)propane-2-sulfonamide,
N-(6-(4-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)-1,4-diazepan-1-yl)pyridin-2-yl)propane-2-sulfonamide,
N-(6-(4-((1-(2-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-1,4-diazepan-1-yl)pyridin-2-yl)propane-2-sulfonamide, and
N-(6-(4-((1-(pyridin-2-yl)-1H-imidazol-4-yl)methyl)piperazin-1-yl)pyridin-2-yl)propane-2-sulfonamide,
optionally as a stereoisomer, including enantiomers and diastereomers, a racemate or a mixture of at least two stereoisomers, including enantiomers and/or diastereomers, in any mixing ratio, or a salt thereof.
12. The compound according to claim 9 , which is selected from:
N-(3-(4-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenyl)propane-2-sulfonamide,
N-(3-(4-((1-(2-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenyl)propane-2-sulfonamide,
N-(3-(4-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenyl)cyclopropanesulfonamide,
N-(3-(4-((1-(3-fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenyl)propane-2-sulfonamide,
N-(3-(4-((1-phenyl-1H-pyrazol-4-yl)methyl)piperazin-1-yl)phenyl)methanesulfonamide,
N-(3-(4-((1-phenyl-1H-pyrazol-4-yl)methyl)piperazin-1-yl)phenyl)propane-2-sulfonamide,
3-(4-((1-phenyl-1H-pyrazol-4-yl)methyl)piperazin-1-yl)phenol,
N-(3-(4-((1-(pyridin-2-yl)-1H-pyrazol-4-yl)methyl)piperazin-1-yl)phenyl)propane-2-sulfonamide, and
N-(6-(4-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)-1,4-diazepan-1-yl)pyridin-2-yl)propane-2-sulfonamide,
optionally as a stereoisomer, including enantiomers and diastereomers, a racemate or a mixture of at least two stereoisomers, including enantiomers and/or diastereomers, in any mixing ratio, or a salt thereof.
13. A process for the production of a compound of formula V according to claim 4 :
wherein R 1 , R 2 , R 3 , R 4 , R 5 , n and m as well as
are as defined in claim 4 ,
wherein a compound of formula VIII or its suitable salt
wherein R 1 , R 2 , and R 5 are as defined in claim 4 , is reacted with a compound of formula X
wherein m is as defined in claim 4 and X is a leaving group, wherein the reaction is carried out in the presence of a base in an aprotic solvent, leading to a compound of formula IX,
wherein R 1 , R 2 , R 5 and m are as defined in claim 4 ,
followed by reacting the compound of formula IX with a compound of formula XI
wherein R 3 , R 4 and n are as defined in claim 4 , wherein the reaction is carried out in the presence of a copper salt and sodium ascorbate in a mixture of protic organic solvent and water, leading to a compound of formula (V).
14. The process according to claim 13 , wherein, in the reaction between the compound of formula (VIII) and the compound of formula (X), the base is Et 3 N, the aprotic solvent is tetrahydrofuran (THF), and the reaction is carried out at a temperature range of 25-75° C.
15. The process according to claim 13 , wherein, in the reaction between the compound of formula (IX) and the compound of formula (XI), the copper salt is CuSO 4 .5H 2 O, the mixture of protic organic solvent and water is a mixture of t-BuOH:H 2 O 1:1 and the reaction is carried out at room temperature.
16. A pharmaceutical composition which comprises a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.
17. A method for treating pain in a subject in need thereof, comprising administration of an effective amount of a compound according to claim 1 .
18. The method of claim 17 , wherein the pain is medium to severe pain, visceral pain, chronic pain, cancer pain, migraine, inflammatory pain, acute pain or neuropathic pain, allodynia or hyperalgesia.